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ABSTRACT
Ve present results from a mathematical analysis that is aimed at finding the best way
to sequence the three traditional cancer treatments: surgery (S), chemotherapy (C) and
radiotherapy (R). The mathematical model tracks the temporal evolution of the primary
tumor and its associated metastases, and incorporates the primary tumor's effect on the
dormancy and growth of the metastases. We show that the SCR schedule (i.e., surgery
followed by chemotherapy followed by radiotherapy) achieves a higher cure probability than
SRC if the primary tumor is sufficiently large or if the metastatic population is sufficiently
large relative to the primary tumor. We also show that a novel schedule, SRCR, which splits
the radiotherapy regimen into two disjoint portions, is optimal among all schedules, provided
that the patient's dormant metastatic tumors do not become vascularized within about 40
days after surgery.
Running title: Sequencing Multimodal Treatments
1Person to whom correspondence should be addressed
Introduction
For decades, the main treatment modalities for most solid tumors have been surgery, radio-
therapy and chemotherapy. However, for some forms of cancer, a consensus has not been
reached for the optimal sequencing of these three modes of treatment; e.g., see [l]-[2] for
candidate sequences in breast cancer. This difficult sequencing decision has become further
complicated in recent years as the relationship between angiogenesis and metastasis has been
revealed [3]-[5]. Angiogenesis research has led to a rethinking of the detailed scheduling of
chemotherapy [6], and it is conceivable that it should also shed new light on the sequencing
decision.
In an attempt to better understand this sequencing decision, we formulate a mathemat-
ical model that follows a primary tumor and its secondary metastases during the course
of multimodal treatment, and incorporates the primary tumor's effect on the dormancy,
vascularization and subsequent growth of the metastases. Under some assumptions on the
parameter values, which are expressed in simple biological terms, we compare the cancer
cure probabilities of the six permutation schedules (i.e., SCR, CSR, CRS, SRC, RSC, RCS)
and derive a novel schedule that is optimal among all feasible strategies.
The Model
Model Description. The mathematical model is stated in the Appendix and described
in detail in a companion paper [7]. Here we outline the model in nonmathematical terms.
Our deterministic model keeps track of the size of the primary tumor and the size and
2
number of distant metastases. The primary tumor grows exponentially, and is affected by
all three forms of treatment. Surgery is instantaneous and kills a fixed fraction of cells.
Our toxicity constraints assume that radiotherapy and chemotherapy are applied at fixed
dose rates for a fixed duration of time. The timing of the three treatments is arbitrary,
except that they cannot be given simultaneously. Inserting rest periods in our model is not
beneficial, and so we do not consider schedules that have time gaps between treatments. We
assume that a given dose of chemotherapy or radiotherapy kills a fixed fraction of remaining
tumor cells. This assumption is consistent with Skipper's [8] :'log cell kill" hypothesis for
chemotherapy, and our radiotherapy assumption captures the linear killing term in the linear-
quadratic model of radiobiology, which is responsible for the great majority of cell killing
under standard fractionation schemes [9]. While radiotherapy kills only cells in the primary
tumor, chemotherapy affects both the primary and metastatic tumors (with the same killing
rate).
A crucial role in our model is played by a critical tumor size that we refer to as the
vascular threshold, which is about 105 cells [10]. WVe consider a primary or metastatic tumor
to be vascular if it is larger than the vascular threshold, and avascular otherwise. A vascular
(primary or metastatic) tumor sheds cells at a rate that is proportional to its size raised to a
certain power. While our model allows this power coefficient to take on any value between 0
and 1, 2/3 [11] is a natural value because the probability of shedding from the tumor surface
is linear in the microvessel count [3]. Each cell that is shed initiates a new metastasis, which
grows exponentially (at a different rate than the primary tumor) until it reaches the vascular
threshold, at which point it lays dormant; this dormancy, which is due to a lack of nutrients,
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is characterized by a balance between cell division and cell apoptosis and necrosis 5]. A
dormant tumor incurs an angiogenic delay until it becomes vascularized; note that dormant
tumors shrunk by chemotherapy need to regrow to the vascular threshold before returning to
a state of dormancy. Following [3]-[5], we assume that this angiogenic delay is shorter in the
presence of an avascular primary tumor and is longer when the primary tumor is vascular.
While this phenomenon is well documented for surgical removal of the primary tumor, it is
not yet known whether this reduction in angiogenic delay also results from tumor shrinkage
due to chemotherapy or radiotherapy (see [12]-[13] for contradictory results for radiotherapy
of mice). Finally, to better mimic a stochastic model and prevent misleading results, we
incorporate a threshold that delays the first vascularization of a dormant tumor.
The "Poisson model", which is commonly employed to calculate the tumor control prob-
ability in radiotherapy [14], is used to compute the cancer cure probability. According to
this model, a fixed fraction of all (primary and metastatic) tumor cells are clonogenic (i.e.,
capable of regrowing the tumor), the number of remaining tumor cells at each point in time
has a Poisson probability distribution, and a cure is achieved if all clonogenic cells are killed
or removed. Because the cancer burden (i.e., total number of cancer cells) is not necessarily
minimized at the end of treatment (e.g., cell killing by adjuvant radiotherapy may be less
than metastatic growth), we need to find, for any given treatment schedule, the minimum
cancer burden throughout the course of treatment.
The model begins at the time of presentation, when the clinician observes the size of the
primary tumor and the size and number of observable metastases. To estimate the mean
amount of subclinical metastases at the time of presentation, we use a dynamic stochastic
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model in which cells are shed according to a nonhomogeneous Poisson process (at the shed-
ding rate described earlier) and the time for a metastasis to grow (including the angiogenic
delay) from a single cell to the detection limit is an exponential random variable.
Assumptions. WVe now state eight assumptions that are used to enable an exact analysis
of our model. The assumptions are stated in precise mathematical terms in the Appendix;
Assumption 8 in the Appendix is actually less stringent than Assumption 8 below, but the
version in the Appendix is difficult to state in nonmathematical terms.
Assumption 1. At the time of presentation, all subclinical metastases are dormant.
Assumption 2. A single metastatic cell cannot grow to the vascular threshold (about 10 s
cells [10]) during the full regimen of radiotherapy (about 40 days).
Assumption 3. Surgery, the full allotment of chemotherapy and the full allotment of radio-
therapy are each effective enough to shrink the initial primary tumor to an avascular size
(i.e., below 105 cells).
Assumption 4. Dormant metastatic tumors treated with the full regimen of chemotherapy
do not grow back to their pre-chemotherapy size during the subsequent full regimen of
radiotherapy (about 40 days).
Assumption 5. The number of cells shed by the primary tumor during an initial full regimen
of radiotherapy is less than or equal to the number of primary cells killed by post-radiotherapy
surgery plus chemotherapy.
Assumption 6. The kill rate of radiotherapy is greater than or equal to the kill rate of
chemotherapy.
Assumption 7. Metastatic tumors grow at least as fast as the primary tumor.
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Assumption 8. If treatment is initiated by surgery and is followed immediately by the full
regimen of radiotherapy, then no dormant tumors become vascularized during radiotherapy
(about 40 days).
Detailed justification of Assumptions 2-8 can be found in [7]. There may be some very
aggressive (and probably incurable) tumors for which Assumptions 4 and 8 do not hold;
otherwise, these seven assumptions are not controversial. In contrast, Assumption 1 is made
for purposes of analytical tractability, and may not hold in practice. However, Assumption 1
is not too unreasonable (and is unlikely to affect our results), because the angiogenic delay
for a dormant metastatic tumor in the presence of a primary tumor is usually several years
[15], whereas it takes several months for a metastatic tumor to grow from a single cell to the
vascular threshold, and to grow from the vascular threshold to the level of detection [16].
Results
A detailed mathematical analysis of our problem appears in [7]. The results from this
analysis are summarized below. WVe say that schedule A is "better" (or "more effective")
than schedule B if schedule A achieves a cancer cure probability that is at least as high as
Schedule B. Result 1 uses only Assumption 1. All other results depend upon Assumptions 2-
7, and Result 4 also relies on Assumption 1. Assumption 8 is only required for Result 8.
Estimation of dormant metastases. Our estimate of the expected number of dormant
metastases at the time of presentation reveals the following surprising result.
Result 1: The expected number of dormant metastases at the time of presentation is inde-
pendent of the number and size of vascular metastases observed at the time of presentation.
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Permutation schedules. Result 2 compares the three CR permutation schedules.
Result 2: Earlier surgery is more effective for CR schedules; i.e., SCR is better than CSR.
which is better than CRS.
WVe need to introduce some notation to state Result 3, which compares the three RC
permutation schedules. For an arbitrary schedule A, let nA be the number of offspring
from dormant-then-vascular cells that are produced during the radiotherapy portion of the
treatment. Let s be the number of cells produced by shedding (i.e., the shed cells plus their
progeny) before the primary tumor is shrunk to an avascular size by neoadjuvant radiation.
Result 3: RSC and RCS have the same effectiveness. RSC is better than SRC if nSRC -
nRSC > S.
In Result 4, we compare the two most commonly prescribed multimodal treatments, SRC
and SCR. The term "sufficiently large" in Result 4 represents some complex mathematical
inequalities (two inequalities for the primary tumor and two inequalities for the metastases
relative to the primary tumor) that can be found in Proposition 5 of [7].
Result 4: If the detectable metastatic population is sufficiently large relative to the primary
tumor at the time of presentation, or if the primary tumor is sufficiently large at the time
of presentation, then SCR is better than SRC. If there is no detectable metastases and the
primary tumor is sufficiently small at the time of presentation, then SRC is better than SCR.
Novel schedules. The detailed mathematical comparison of SCR and SRC in [7] re-
veals the strengths and weaknesses of each and motivates a novel schedule that combines the
best of both schedules. The crux of this comparison is systemic growth during the sched-
ules' radiotherapy. During SRC's radiotherapy, only existing vascular metastases and newly
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dormant-then-vascular metastases grow. During SCR's radiotherapy, dormant regrowth also
occurs because the dormant tumors were shrunk during the preceding chemotherapy, and so
all metastatic tumors grow. Moreover, SRC achieves its minimum cancer burden at the end
of treatment, whereas SCR mitigates the effect of its larger systemic growth during radio-
therapy by achieving its cancer nadir before administering the full allotment of radiotherapy,
when radiotherapy's killing is exactly balanced by metastatic growth.
We propose a schedule, SRCR, that combines the strengths of SCR and SRC. This
strategy splits the allotment of radiotherapy into two disjoint pieces, which are positioned
before and after chemotherapy. By initiating some adjuvant radiotherapy, SRCR prevents
the prenadir regrowth of dormant metastases that hinders SCR. But SRCR mimics SCR, in
that the amount of pre-chemotherapy radiation administered is chosen so that chemotherapy
begins exactly when the cell killing by pre-chemotherapy radiation is offset by metastatic
growth or the radiotherapy toxicity constraint is reached. We construct the novel schedule
RSCR, which combines the best of CSR and RSC, in an analogous fashion; i.e., the first
portion of radiotherapy is administered until either cell killing equals metastatic growth
or the radiotherapy toxicity constraint is reached. Just as RSC can outperform SRC (see
Result 3), it is also possible for RSCR to be more effective than SRCR.
Results 5 and 6 confirm our conjectures about these novel strategies and Result 7 sum-
marizes the superiority of these schedules.
Result 5: SRCR is better than SCR and SRC.
Result 6: RSCR is better than CSR and RSC.
Result 7: It is always the case that either SRCR or RSCR (or both) is better than all six
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permutation schedules.
Finally, we impose Assumption 8 to derive a stronger result.
Result 8: If Assumption 8 holds, then SRCR is best among all schedules that administer
surgery and the full allotments of radiotherapy and chemotherapy.
Discussion
To our knowledge, this paper represents the first attempt to use a mathematical model to
optimize the sequencing of surgery, radiotherapy and chemotherapy. The model contains
14 parameters, many of which are difficult to measure and exhibit considerable interpa-
tient heterogeneity in a correlated manner [171-[18]. Consequently, we believe it would be
extremely difficult if not i'mpossible to validate this model using clinical data. Without a
model validation, conclusions from a computational study using this model would not be
persuasive. Therefore, we resorted to a purely mathematical approach: we state a number
of assumptions in simple biological terms, and then derive (the mathematical proofs appear
in [7]) a set of results that rely on these assumptions.
Discussion of results. Result 1 states that the knowledge of the number and size of
clinically detectable metastases at the time of presentation does not influence the estimate
for the expected number of dormant metastases at the time of presentation. This result
suggests that at the time of presentation, it is the size of the primary tumor - and not
the size and number of clinically detectable metastases - that provides the most useful
information about the amount of subclinical disease. This counterintuitive result is derived
using queueing theory, where shed cells from the primary tumor correspond to the arrivals to
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the waiting line, and service times correspond to the time between being shed as a solitary
metastatic cell and reaching a clinically detectable size. Result 1 relies on Assumption 1
plus two weak probabilistic assumptions: cells are shed from the primary tumor according
to a nonhomogeneous Poisson process (this assumption is satisfied if the shedding behavior
of each cell is independent of the other cells), and the .service times for each metastasis are
independent and identically distributed (but not necessarily exponential, as in equation (8)).
Results 2 and 3 focus on the timing of surgery. The inherent tradeoff is that later
surgery acts as a "poor man's angiogenesis" by slowing the rate of vascularization of dormant
metastatic tumors, while earlier surgery reduces shedding from the primary tumor. In our
model, the latter effect wins out for CR schedules (i.e., chemotherapy precedes radiation)
because - by Assumption 4 - the avascular and vascular metastases behave the same under
all three CR schedules; i.e., delayed surgery does not reduce the growth capability of dormant
tumors. In contrast, the timing of surgery does affect the rate of vascularization of dormant
metastases in RC schedules, and Result 3 elucidates the tradeoff of delayed vascularization
and primary shedding for the RSC vs. SRC case. Computational results (not shown here)
using representative parameter values for breast cancer do not suggest that one of these
two schedules consistently dominates the other. Although the suboptimality of CSR in
Result 2 may seem surprising in light of the ongoing clinical trial of this schedule by the
Milan Cancer Institute [2], their primary motivation for administering at least a few rounds
of neoadjuvant chemotherapy was not to increase the cure probability, but to increase the
likelihood of breast-conserving surgery [19], which is a factor omitted from our study.
Result 4 compares the two most popular multimodal schedules, SCR and SRC, and reveals
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that chemotherapy should be given before radiation to suppress a large vascular metastatic
population or a suspected (via a large primary tumor) large dormant metastatic population.
This result is consistent with [1], which shows the superiority of SCR over SRC for breast
cancer patients receiving conservative surgery who are at substantial risk for systematic
metastasis.
As explained earlier, a detailed investigation of SCR and SRC (CSR and RSC, respec-
tively) led us to consider SRCR (RSCR, respectively). In these two schedules, the first
portion of radiotherapy is terminated at the point when either radiation killing is offset by
metastatic growth or the radiotherapy toxicity constraint is reached. Results 5 through 7
confirm the superiority of these two novel schedules, and Result 8 shows that SRCR is opti-
mal over all possible schedules if the dormant metastases do not undergo angiogenesis within
about the first 40 days after surgery. There are two noteworthy features of Result 8. First,
this result suggests that optimality can be attained by simply breaking the radiotherapy
regimen into two disjoint segments, and that more sophisticated strategies, such as the in-
tegrated alternating regimen in [201, need not be considered. Second, the proof of Result 8
reveals that the nadir of the cancer burden, and hence the cancer cure probability, in the
SRCR schedule is achieved at the end of chemotherapy, not necessarily at the end of treat-
ment. Nonetheless, administering any post-chemotherapy portion of the radiotherapy may
prolong survival for the uncured cases by improving locoregional control and delaying the
onset of metastases.
Limitations. Although our 14-parameter model captures the first-order effects of the pri-
mary tumor and its shedding, angiogenesis of the primary tumor and its impact on metastatic
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dormancy and growth, and the impact of local and systemic treatment, it is still a very
crude representation of the clinical setting. A key omission in our model is the mutations
that tumor cells accumulate as a result of the microenvironment [21] and treatment [22].
These mutations may cause changes in the radiosensitivity, chemosensitivity, shedding rate,
growth rate and angiogenesis rate of the primary and metastatic tumors. It is difficult to
predict how the inclusion of these issues might affect our results. For example, it has been
argued that it is preferable to administer chemotherapy earlier because the tumor cells have
not accumulated too many mutations [19], and to administer it later, so as to delay acquired
drug resistance. In any case, our omission of tumor heterogeneity requires our results to be
interpreted with caution.
Our model also ignores the detailed timing issues of treatment, such as healing periods
between modes of treatment (however, delays between surgery and adjuvant chemotherapy
of as much as four weeks cause no significant difference in outcome [23]-[24]) and the phar-
macokinetics of chemotherapy. We also ignore any synergistic or antagonistic interactions
between chemotherapy and radiotherapy, because these are drug-specific and often depend
upon the detailed timing of the schedule. Finally, tumor angiogenesis is an extremely com-
plex process involving dozens of factors [15], and our modeling of it is necessarily simplistic.
However, perhaps the model's biggest shortcoming is not related to the tumor biology,
but to the formulation of our decision problem: we model a dynamic stochastic control
problem with imperfect but accumulating information by a dynamic deterministic control
problem with perfect information. In particular, the two novel strategies, SRCR and RSCR,
require the clinician to observe the point in time when radiation killing is dominated by
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metastatic growth, which is impossible with current technology. Nonetheless, knowledge of
an optimal solution in the idealized case of perfect information does provide insights for
managing the more realistic case of imperfect information. More specifically, our analysis
could be operationalized (with considerable validation and calibration), as we outline below
for the SRCR schedule. First, a statistical model (along the lines developed in [25]-[261)
could be used to estimate a one-dimensional quantity representing the metastatic potential
(e.g., the probability of detecting metastases within five years) from information accumulated
by the time of surgery (e.g., size of the primary tumor, amount of detectable metastases,
histological grade, presence of margins, node involvement, hormonal test results). If the
metastatic potential is very high then use SCR, if it is very small use SRC, and if it is
intermediate in value then use a version of SRCR. Also, the schedule can be altered during
the course of treatment as new information becomes available; e.g., if metastasis is observed
during the radiation portion of SRC, then we update the state information and use Result 4
to immediately switch to chemotherapy.
In summary, this research provides a systematic framework for deciding on the sequence
of surgery, radiotherapy and chemotherapy. Our analysis elucidates the tradeoffs that are at
the crux of this complex problem, and derives two novel schedules, SRCR and RSCR, that
may have the potential to enhance cancer cure probabilities.
Appendix
This appendix expresses the mathematical model as a control problem: maximize the
cancer cure probability subject to toxicity constraints. Mathematically, given p(O) and m(O),
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the problem is to
max max e- f [p( t )+d( t) +m (t) ]
r(t),c(t),t tE[O,R+C
cancer cure probability
subject to
= [ roth
growth
- kr(t)
radiotherapy
- kc(t)
chemotherapy
= [m{d(t)<(t) 
- kc(t)
regrowth chemotherapy
A (p(t)) I{p( t)>}
metastatic shedding
(2)- sI{t=t]p(t),
surgery
- (aIp a(t) } + )aI~pat)< {te }]d(t), (3)
angiogenesis
+ [(aI{p(t)>,} + aI{p(t)<U}) I{tta}1] d(t)I 
angiogenesis
kc(t) ]r,
chemotherapy
c(t) {O, 1}, r(t) + c(t) < 1,
R+C
r(t) dt = R,
R+C
c(t) dt = C,
0
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(1)
p(t)
primary
d(t)
dormant
rh(t)
metastases
+ [ Ym
gro.wth
r(t) {0,1},
(4)
(5)
(6)
(7)
Xv\fCt)f - 'U3 p(O)]d(O) =37 + (8)
d(T) [avIfp( )>} + a{p(,)<v} d = U (9)
angiogenesis initiation.
and
[d(o)-( f[a(tVI{P(),>i}+a{p()• dr) if t > t
d(t) (10)
regrowth threshold d(O) otherwise.
The model is described in detail in [7], and here we restrict ourselves to several comments
on its nonobvious features. Assumption 2 allows us to ignore the entry into the dormant
compartment of newly shed metastases that reach the vascular threshold of cells. As
explained in [7], this assumption - together with the calculation of the cancer cure probability
and Assumption 1 - allows us to aggregate all dormant metastases into one compartment
in (3) and all growing metastases into another compartment in (4). The indicator function
I{t>t,,} in (3), where the threshold t is defined in (9), delays the first vascularization of
a dormant metastasis, so that our deterministic model mimics a stochastic modeL. The
regrowth of dormant metastases, which have been shrunk by chemotherapy, to the vascular
threshold is incorporated into the first term on the right side of (3) by the indicator function
I{d(t)<J(t)- The threshold d(t) in (10), along with Assumption 2, ensures that the shrunk
dormant metastases regrow only to their original size. The estimate of the initial dormant
metastases in (8) uses Assumption 1 and is the result of a queueing theory analysis. In
15
III
this equation, the parameter is the reciprocal of the mean time that it takes for a single
metastatic cell to reach the level of detection in the presence of the primary tumor; hence,
if D is the detection limit in terms of cells, then -1 = aJl + ln(D)/Tym.
Below we express the eight assumptions appearing in the text more precisely in terms of
the model parameters. As noted earlier, Assumption 8 below is actually less stringent than
the Assumption 8 that appears in the text.
Assumption 1. At time 0, all subclinical metastases have exactly v cells.
Assumption 2. 7ymR < lnv.
Assumption 3. p > max{e-s, e(- ~) c e(7-k.)R}.
Assumption 4. (k - ,m)C > 7yR.
Assumption 5. p(0)e(-tk)R(1 -s+(^y-kc)C)
Assumption 6. kr > k,.
Assumption 7. my, > .
Assumption 8. min CR, In- U a-y)p(O)e-(O)>I -inm(O) where we take
-ln(O) = oo.
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